Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Cancer Discov. 2013 Mar 1;3(5):548–563. doi: 10.1158/2159-8290.CD-12-0446

Figure 1. KRAS mutant NSCLC cells are selectively sensitive to MEK, RAF and IGF1R inhibitors.

Figure 1

(A-B) Twenty-five NSCLC cell lines (thirteen KRAS mutant and twelve KRAS wild-type) were transfected with KRAS, KRAS-OTP or control siRNAs. Relative cell viability (A) and apoptosis (B) were measured 96 h after transfection.

(C-J) Twenty-five NSCLC cell lines were treated for 72 h with serial dilutions of MEK (B and C), IGF1R (E and F), RAF (G), EGFR (H), PI3K (I) and mTOR (J) inhibitors. Left panels show curves representing average values for each KRAS genotype (mean ± SEM). Right panels show single data-points representing individual cell lines at three selected drug doses.